Tumor thrombosis is a relatively uncommon complication of renal cell carcinoma (RCC), and its diagnosis has therapeutic and prognostic implication. Computerized tomography (CT) is the primary imaging modality for staging RCC, but it has low sensitivity to differentiate between tumor thrombus and bland or benign thrombus. 18-fluorodeoxyglucose positron emission tomography/ CT (PET/CT) has a limited role in diagnosis and staging of RCC, but its diagnostic accuracy is considerably high for detection of metabolically active tumor thrombus. We are presenting a case of metastatic left-sided RCC with massive hypermetabolic tumor thrombus extending from left kidney to left renal vein and inferior vena cava giving an interesting "Suspension Bridge" appearance on PET/CT images. 
Introduction
Renal cell carcinoma (RCC) is the most common solid tumor of the kidneys, accounting for 3% of all malignancies and representing the seventh leading cause of cancer. [1] An unusual hallmark of RCC is the biological predisposition for vascular invasion, with the extension of tumor thrombus into the renal veins and inferior vena cava (IVC) in 24% and 12% of all cases, respectively. [2] Preoperative diagnosis of tumor thrombosis and its extent is paramount as it needs surgical resection (nephrectomy and thrombectomy) to have local control and prognostic implication as about 33% patients also have concurrent metastasis. [1] RCC is also associated with hypercoagulable state and development of bland IVC thrombus which usually do not require thrombectomy. The differentiation between tumor thrombus and bland thrombus is not usually possible with contrast-enhanced computerized tomography (CECT) or magnetic resonance imaging (MRI). [3] However, [4] We are presenting a case of the left RCC with extensive 18 FDG tumor thrombus in the left renal vein and IVC mimicking "Suspension Bridge" on PET/CT imaging.
Massive Tumor Thrombus in Left Renal

Case Report
A 72-year-old male presented with a history of painful sternal swelling and fine needle aspiration biopsy was positive for metastatic cancer most like renal origin. An 18 FDG PET/CT study was advised for localization of primary tumor and staging. The patient was administered 190 MBq (3 MBq/kg) of 18 FDG (fasting blood glucose 90 mg/dl), and after 55 min of uptake period, imaging was performed using Celesteion, Toshiba, Japan. 
Discussion
CECT is the imaging of choice for diagnosis and staging of RCC with a reported sensitivity of 92%. [5] However,
18
FDG PET/CT has a limited role for RCC as excreted 18 FDG may obscure or mask the lesions of the kidneys. Therefore, 18 FDG PET/CT is not recommended for diagnosis and staging of RCC in current guidelines. [6] In the management of RCC, detection of tumor thrombosis, its extent, and differentiation between bland or venous thrombosis is important. Venous or bland thrombosis is commonly seen in cancer which is managed with anticoagulant therapy, while tumor thrombosis requires aggressive multimodality therapeutics. Differentiation between these two entities is important for therapeutic and prognostic point of view which may not be possible with CECT or MRI. [3] Recent data show that 18 FDG PET/CT has higher sensitivity and diagnostic accuracy for detection of tumor thrombosis and bony metastasis as compared with CT and bone scan, respectively. [7] IVC is the most common site with a linear shaped 18 FDG uptake by viable tumor thrombus. SUV max of tumor thrombus in our case was significantly high (renal vein: 13.4 and IVC: 16.6) which is in concordance with published reports. [6] In the present case, hypermetabolic tumor thrombus was very extensive, extending from left kidney passing through left renal vein and entering into IVC with antegrade (infrahepatic) and retrograde extensions giving an appearance of suspension bridge on maximum intensity projection and coronal images. To the best of our search, we could not find any report in literature with such an extensive tumor thrombus in RCC giving this type of interesting appearance.
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